Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 5/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702241 | 0.77 | BCL2L1 (0.42) | BCL2L1BADCES1GRIA1GRIA2 | |
| SCHEMBL25033705 | 0.76 | CES1 (0.35) | BCL2L1BADCES1CCR4NOS3 | |
| SCHEMBL10928179 | 0.75 | LMNA (0.40) | BCL2L1BADCES1 | |
| SCHEMBL1284960 | 0.74 | BCL2L1 (0.58) | BCL2L1BADCES1GRIA1GRIA2 | |
| SCHEMBL19296831 | 0.74 | HTR2A (0.39) | ALDH1A1HPGDCETP | |
| SCHEMBL16646844 | 0.74 | BCL2L1 (0.52) | BCL2L1BADCES1GRIA1GRIA2 | |
| SCHEMBL9362457 | 0.73 | CA2 (0.43) | BCL2L1BADCES1GRIA1GRIA2 | |
| SCHEMBL20932959 | 0.73 | PNMT (0.40) | — | |
| SCHEMBL3797823 | 0.73 | BCL2L1 (0.56) | BCL2L1BADGRIA1GRIA2GRIA3 | |
| SCHEMBL16527208 | 0.72 | BCL2L1 (0.50) | BCL2L1BADCES1GRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | BCL2L1 2582/4885BAD 4469/4885CES1 2445/4885 |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | BCL2L1 627/4885BAD 471/4885CES1 3492/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | BCL2L1 966/4885BAD 1057/4885CES1 1974/4885 |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | BCL2L1 960/4885BAD 755/4885CES1 3347/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | BCL2L1 960/4885BAD 755/4885CES1 3347/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | BCL2L1 627/4885BAD 471/4885CES1 3492/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | BCL2L1 627/4885BAD 471/4885CES1 3492/4885 |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | BCL2L1 326/4885BAD 1884/4885CES1 4071/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | BCL2L1 2582/4885BAD 4469/4885CES1 2445/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | BCL2L1 326/4885BAD 1884/4885CES1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.